Protein-Protein Interactions: An Overview

Protein-Protein Interactions in Drug Discovery

Volumn 56, Issue , 2013, Pages 1-19

  Ottman, Christian ^a  

^a CHEMICAL GENOMICS CENTRE OF THE MAX PLANCK SOCIETY   (Germany)

Author keywords

Drug discovery; Human physiology; Inhibition; Interactome; Protein protein interaction; Regulation

Indexed keywords

ENZYME INHIBITION; PHYSIOLOGY;

DRUG DISCOVERY; HUMAN PHYSIOLOGY; INTERACTOME; PROTEIN-PROTEIN INTERACTIONS; REGULATION;

PROTEINS;

EID: 85016490954     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527648207.ch1     Document Type: Chapter

References (72)

1. Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B.J., Anderson, D.J., Alvarado, R., Ludlam, M.J., Stokoe, D., Gloor, S.L., Vigers, G., Morales, T., Aliagas, I., Liu, B., Sideris, S., Hoeflich, K.P., Jaiswal, B.S., Seshagiri, S., Koeppen, H., Belvin, M., Friedman, L.S., and Malek, S. (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature, 464, 431-435.
2. Poulikakos, P.I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M.T., Salton, M., Dahlman, K.B., Tadi, M.,Wargo, J.A., Flaherty, K.T., Kelley, M.C., Misteli, T., Chapman, P.B., Sosman, J.A., Graeber, T.G., Ribas, A., Lo, R.S., Rosen, N., and Solit, D.B. (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E). Nature, 480, 387-390.
3. Heidorn, S.J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J.S., Springer, C.J., Pritchard, C., and Marais, R. (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell, 140, 209-221.
4. Hopkins, A.L. and Groom, C.R. (2002) The druggable genome. Nature Reviews Drug Discovery, 9, 727-730.
5. Overington, J.P., Al-Lazikani, B., and Hopkins, A.L. (2006) How many drug targets are there? Nature Reviews Drug Discovery, 5, 993-996.
6. Venkatesan, K., Rual, J.F., Vazquez, A., Stelzl, U., Lemmens, I., Hirozane- Kishikawa, T., Hao, T., Zenkner, M., Xin, X., Goh, K.I., Yildirim, M.A., Simonis, N., Heinzmann, K., Gebreab, F., Sahalie, J.M., Cevik, S., Simon, C., de Smet, A.S., Dann, E., Smolyar, A., Vinayagam, A., Yu, H., Szeto, D., Borick, H., Dricot, A., Klitgord, N., Murray, R.R., Lin, C., Lalowski, M., Timm, J., Rau, K., Boone, C., Braun, P., Cusick, M.E., Roth, F.P., Hill, D.E., Tavernier, J.,Wanker, E.E., Barabasi, A.L., and Vidal, M. (2009) An empirical framework for binary interactome mapping. Nature Methods, 6, 83-90.
7. Stumpf, M.P., Thorne, T., de Silva, E., Stewart, R., An, H.J., Lappe, M., and Wiuf, C. (2008) Estimating the size of the human interactome. Proceedings of the National Academy of Sciences of the United States of America, 105, 6959-6964.
8. Wellbrock, C., Karasarides, M., and Marais., R. (2004) The Raf proteins take centre stage. Nature Reviews Molecular Cell Biology, 5, 875-885.
9. Zeng, L., Imamoto, A., and Rosner, M.R. (2008) Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target. Expert Opinion on Therapeutic Targets, 12, 1275-1287.
10. Bernstein, B.W. and Bamburg, J.R. (2010) ADF/cofilin: a functional node in cell biology. Trends in Cell Biology, 20, 187-195.
11. Lawson, C. and Wolf, S. (2009) ICAM-1 signaling in endothelial cells. Pharmacology Reports, 61, 22-32.
12. Shih, V.F., Tsui, R., Caldwell, A., and Hoffmann, A. (2011) A single NFkB system for both canonical and 14j 1 Protein-Protein Interactions: An Overview non-canonical signaling. Cell Research, 21, 86-102.
13. Tzivion, G., Dobson, M., and Ramakrishnan, G. (2011) FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochimica et Biophysica Acta, 1813, 1938-1945.
14. Liu, J.O. (2009) Calmodulin-dependent phosphatase, kinases, and transcriptional corepressors involved in T-cell activation. Immunological Reviews, 228, 184-198.
15. Shitashige, M., Hirohashi, S., and Yamada, T. (2008)Wnt signaling inside the nucleus. Cancer Science, 99, 631-637.
16. Fu, H., Coburn, J., and Collier, R.J. (1993) The eukaryotic host factor that activates exoenzyme S of Pseudomonas aeruginosa is a member of the 14-3-3 protein family. Proceedings of the National Academy of Sciences of the United States of America, 90, 2320-2324.
17. Coburn, J., Wyatt, R.T., Iglewski, B.H., and Gill, D.M. (1989) Several GTP-binding proteins, including p21c-H-ras, are preferred substrates of Pseudomonas aeruginosa exoenzyme S. The Journal of Biological Chemistry, 264, 9004-9008.
18. Nooren, I.M. and Thornton, J.M. (2003) Diversity of protein-protein interactions. EMBO Journal, 22, 3486-3492.
19. Wong,W. and Scott, J.D. (2004) AKAP signalling complexes: focal points in space and time. Nature Reviews Molecular Cell Biology, 5, 959-970.
20. Claperon, A. and Therrien, M. (2007) KSR and CNK: two scaffolds regulating RASmediated RAF activation. Oncogene, 26, 3143-3158.
21. Oltersdorf, T., Elmore, S.W., Shoemaker, A.R., Armstrong, R.C., Augeri, D.J., Belli, B.A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P.J., Joseph, M. K., Kitada, S., Korsmeyer, S.J., Kunzer, A.R., Letai, A., Li, C., Mitten, M.J., Nettesheim, D.G., Ng, S., Nimmer, P.M., O'Connor, J.M., Oleksijew, A., Petros, A. M., Reed, J.C., Shen, W., Tahir, S.K., Thompson, C.B., Tomaselli, K.J., Wang, B., Wendt, M.D., Zhang, H., Fesik, S.W., and Rosenberg, S.H. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 435, 677-681.
22. Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., and Liu, E.A. (2004) In vivo activation of the p53 pathway by smallmolecule antagonists of MDM2. Science, 303, 844-848.
23. He, M.M., Smith, A.S., Oslob, J.D., Flanagan,W.M., Braisted, A.C., Whitty, A., Cancilla, M.T.,Wang, J., Lugovskoy, A.A., Yoburn, J.C., Fung, A.D., Farrington, G., Eldredge, J.K., Day, E.S., Cruz, L.A., Cachero, T.G., Miller, S.K., Friedman, J.E., Choong, I.C., and Cunningham, B.C. (2005) Small-molecule inhibition of TNFalpha. Science, 310, 1022-1025.
24. Cianci, C., Langley, D.R., Dischino, D.D., Sun, Y., Yu, K.L., Stanley, A., Roach, J., Li, Z., Dalterio, R., Colonno, R., Meanwell, N. A., and Krystal, M. (2004) Targeting a binding pocket within the trimer-ofhairpins: small-molecule inhibition of viral fusion. Proceedings of the National Academy of Sciences of the United States of America, 101, 15046-15051.
25. Andries, K., Moeremans, M., Gevers, T., Willebrords, R., Sommen, C., Lacrampe, J., Janssens, F., and Wyde, P.R. (2003) Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antiviral Research, 60, 209-219.
26. Ohtsuka, M., Konno, F., Honda, H., Oikawa, T., Ishikawa, M., Iwase, N., Isomae, K., Ishii, F., Hemmi, H., and Sato, S. (2002) PPA250 [3-(2,4-difluorophenyl)-6- [2-[4-(1H-imidazol-1-ylmethyl) phenoxy] ethoxy]-2-phenylpyridine], a novel orally effective inhibitor of the dimerization of inducible nitric-oxide synthase, exhibits an anti-inflammatory effect in animal models of chronic arthritis. Journal of Pharmacology and Experimental Therapeutics, 303, 52-57.
27. Davey, D.D., Adler, M., Arnaiz, D., Eagen, K., Erickson, S., Guilford,W., Kenrick, M., Morrissey, M.M., Ohlmeyer, M., Pan, G., Paradkar, V.M., Parkinson, J., Polokoff, M., Saionz, K., Santos, C., Subramanyam, B., Vergona, R.,Wei, R.G., Whitlow, M., Ye, B., Zhao, Z.S., Devlin, J.J., and Phillips, G. (2007) Design, synthesis, and activity of 2-imidazol-1-ylpyrimidine derived inducible nitric oxide synthase References j15 dimerization inhibitors. Journal of Medicinal Chemistry, 50, 1146-1157.
28. Chu, G.H., Le Bourdonnec, B., Gu, M., Ajello, C.W., Leister, L.K., Sellitto, I., Cassel, J.A., Tuthill, P.A., O'Hare, H., Dehaven, R.N., and Dolle, R.E. (2009) Design and synthesis of imidazopyrimidine derivatives as potent iNOS dimerization inhibitors. The Open Medicinal Chemistry Journal, 18, 8-13.
29. Erbe, D.V., Wang, S., Xing, Y., and Tobin, J. F. (2002) Small molecule ligands define a binding site on the immune regulatory protein B7.1. The Journal of Biological Chemistry, 277, 7363-7368.
30. Yoakim, C., Ogilvie,W.W., Goudreau, N., Naud, J., Hachle, B., O'Meara, J.A., Cordingley, M.G., Archambault, J., and White, P.W. (2003) Discovery of the first series of inhibitors of human papillomavirus type 11: inhibition of the assembly of the E1-E2-Origin DNA complex. Bioorganic and Medicinal Chemistry Letters, 13, 2539-2541.
31. Kenny, C.H., Ding, W., Kelleher, K., Benard, S., Dushin, E.G., Sutherland, A.G., Mosyak, L., Kriz, R., and Ellestad, G. (2003) Development of a fluorescence polarization assay to screen for inhibitors of the FtsZ/ZipA interaction. Analytical Biochemistry, 323, 224-233.
32. Thanos, C.D., DeLano,W.L., and Wells, J. A. (2006) Hot-spot mimicry of a cytokine receptor by a small molecule. Proceedings of the National Academy of Sciences of the United States of America, 103, 15422-15427.
33. Koblish, H.K., Zhao, S., Franks, C.F., Donatellim, R.R., Tominovich, R.M., LaFrance, L.V., Leonard, K.A., Gushue, J. M., Parks, D.J., Calvo, R.R., Milkiewicz, K. L., Marugan, J.J., Raboisson, P., Cummings, M.D., Grasberger, B.L., Johnson, D.L., Lu, T., Molloy, C.J., and Maroney, A.C. (2006) Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Molecular Cancer Therapeutics, 5, 160-169.
34. Weitz-Schmidt, G., Welzenbach, K., Dawson, J., and Kallen, J. (2004) Improved lymphocyte function-associated antigen-1 (LFA-1) inhibition by statin derivatives: molecular basis determined by X-ray analysis and monitoring of LFA-1 conformational changes in vitro and ex vivo. The Journal of Biological Chemistry, 279, 46764-46771.
35. Gadek, T.R., Burdick, D.J., McDowell, R.S., Stanley, M.S., Marsters, J.C. Jr., Paris, K.J., Oare, D.A., Reynolds, M.E., Ladner, C., Zioncheck, K.A., Lee,W.P., Gribling, P., Dennis, M.S., Skelton, N.J., Tumas, D.B., Clark, K.R., Keating, S.M., Beresini, M.H., Tilley, J.W., Presta, L.G., and Bodary, S.C. (2002) Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science, 295, 1086-1089.
36. Marletta, M. (1994) Nitric oxide synthase: aspects concerning structure and catalysis. Cell, 78, 927-930.
37. Crane, B.R., Arvai, A.S., Ghosh, D.K., Wu, C.Q., Getzoff, E.D., Stuehr, D.J., and Tainer, J.A. (1998) Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. Science, 279, 2121-2126.
38. Li, H., Raman, C.S., Glaser, C.B., Blasko, E., Young, T.A., Parkinson, J.F., Whitlow, M., and Poulos, T.L. (1999) Crystal structures of zinc-free and -bound heme domain of human inducible nitric-oxide synthase. Implications for dimer stability and comparison with endothelial nitricoxide synthase. The Journal of Biological Chemistry, 274, 21276-21284.
39. Cavallo, R.A., Cox, R.T., Moline, M.M., Roose, J., Polevoy, G.A., Clevers, H., Peifer, M., and Bejsovec, A. (1998) Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature, 395, 604-608.
40. Roose, J., Molenaar, M., Peterson, J., Hurenkamp, J., Brantjes, H., Moerer, P., van deWetering, M., Destree, O., and Clevers, H. (1998) The Xenopus Wnt effector XTcf-3 interacts with Grouchorelated transcriptional repressors. Nature, 395, 608-612.
41. Poy, F., Lepourcelet, M., Shivdasani, R.A., and Eck, M.J. (2001) Structure of a human Tcf4-beta-catenin complex. Nature Structural Biology, 8, 1053-1057.
42. Graham, T.A., Ferkey, D.M., Mao, F., Kimelman, D., and Xu,W. (2001) Tcf4 can specifically recognize beta-catenin using alternative conformations. Nature Structural Biology, 8, 1048-1052.
43. Craigie, R. (2002) Retroviral DNA integration, in Mobile DNA II (eds N.L. Craig, R. Craigie, M. Gellert, and A.M. Lambowitz), American Society of Microbiologists, Washington, DC, pp. 613-630.
44. Emiliani, S., Mousnier, A., Busschots, K., Maroun, M., Van Maele, B., Temple, D., Vandekerckhove, L., Moisant, F., Ben- Slama, L., Witvrouw, M., Christ, F., Rain, J. C., Dargemont, C., Debyser, Z., and Benarous, R. (2005) Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. The Journal of Biological Chemistry, 280, 25517-25523.
45. Vanegas, M., Llano, M., Delgado, S., Thompson, D., Peretz, M., and Poeschla, E. (2005) Identification of the LEDGF/p75 HIV-1 integrase-interaction domain and NLS reveals NLS-independent chromatin tethering. Journal of Cell Science, 118, 1733-1743.
46. Cherepanov, P., Ambrosio, A.L., Rahman, S., Ellenberger, T., and Engelman, A. (2005) Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proceedings of the National Academy of Sciences of the United States of America, 102, 17308-17313.
47. Sverdrup, F. and Myers, G. (1997) The E1 proteins, in Human Papillomaviruses (1997) (ed. G. Myers), Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM, pp. 37-53.
48. Seo, Y.S., Muller, F., Lusky, M., Gibbs, E., Kim, H.Y., Phillips, B., and Hurwitz, J. (1993) Bovine papilloma virus (BPV)- encoded E2 protein enhances binding of E1 protein to the BPV replication origin. Proceedings of the National Academy of Sciences of the United States of America, 90, 2865-2869.
49. Sedman, J. and Stenlund, A. (1995) Co-operative interaction between the initiator E1 and the transcriptional activator E2 is required for replicator specific DNA replication of bovine papillomavirus in vivo and in vitro. EMBO Journal, 14, 6218-6228.
50. Abbate, E.A., Berger, J.M., and Botchan, M. R. (2004) The X-ray structure of the papillomavirus helicase in complex with its molecular matchmaker E2. Genes and Development, 18, 1981-1996.
51. Wang, Y., Coulombe, R., Cameron, D.R., Thauvette, L., Massariol, M.J., Amon, L.M., Fink, D., Titolo, S., Welchner, E., Yoakim, C., Archambault, J., and White, P.W. (2004) Crystal structure of the E2 transactivation domain of human papillomavirus type 11 bound to a protein interaction inhibitor. The Journal of Biological Chemistry, 279, 6976-6985.
52. Isaacs, A. and Lindenmann, J. (1957) Virus interference. I. The interferon. Proceedings of the Royal Society London (Biological Sciences), 147, 258-267.
53. Borden, E.C., Sen, G.C., Uze, G., Silverman, R.H., Ransohoff, R.M., Foster, G.R., and Stark, G.R. (2007) Interferons at age 50: past, current and future impact on biomedicine. Nature Reviews Drug Discovery, 6, 975-990.
54. Eizirik, D.L., Colli, M.L., and Ortis, F. (2009) The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nature Reviews Endocrinology, 5, 219-226.
55. Thomas, C., Moraga, I., Levin, D., Krutzik, P.O., Podoplelova, Y., Trejo, A., Lee, C., Yarden, G., Vleck, S.E., Glenn, J.S., Nolan, G.P., Piehler, J., Schreiber, G., and Garcia, K.C. (2011) Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell, 146, 621-632.
56. Kollias, G., Douni, E., Kassiotis, G., and Kontoyiannis, D. (1999) On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunological Reviews, 169, 175-194.
57. Carswell, E.A., Old, L.J., Kassel, R.L., Green, S., Fiore, N., and Williamson, B. (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proceedings of the National Academy of Sciences of the United States of America, 72, 3666-3670.
58. Sugarman, B.J., Aggarwal, B.B., Hass, P.E., Figari, I.S., Palladino, M.A. Jr., and Shepard, H.M. (1985) Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science, 230, 943-945.
59. Kull, F.C. Jr. (1988) The TNF receptor in TNF-mediated cytotoxicity. Natural Immunity and Cell Growth Regulation, 7, 254-265.
60. Aggarwal, B.B., Kohr,W.J., Hass, P.E., Moffat, B., Spencer, S.A., Henzel, W.J., Bringman, T.S., Nedwin, G.E., Goeddel, D. V., and Harkins, R.N. (1985) Human tumor necrosis factor. Production, purification, and characterization. The Journal of Biological Chemistry, 260, 2345-2354.
61. Eck, M.J. and Sprang, S.R. (1989) The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. The Journal of Biological Chemistry, 264, 17595-17605.
62. Morelli, X., Bourgeas, R., and Roche, P. (2011) Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I). Current Opinion in Chemical Biology, 15, 475-481.
63. McMillan, K., Adler, M., Auld, D.S., Baldwin, J.J., Blasko, E., Browne, L.J., Chelsky, D., Davey, D., Dolle, R.E., Eagen, K.A., Erickson, S., Feldman, R.I., Glaser, C. B., Mallari, C., Morrissey, M.M., Ohlmeyer, M.H., Pan, G., Parkinson, J.F., Phillips, G. B., Polokoff, M.A., Sigal, N.H., Vergona, R., Whitlow, M., Young, T.A., and Devlin, J. J. (2000) Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proceedings of the National Academy of Sciences of the United States of America, 97, 1506-1511.
64. Lepourcelet, M., Chen, Y.N., France, D.S., Wang, H., Crews, P., Petersen, F., Bruseo, C., Wood, A.W., and Shivdasani, R.A. (2004) Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell, 5, 91-102.
65. Christ, F., Voet, A., Marchand, A., Nicolet, S., Desimmie, B.A., Marchand, D., Bardiot, D., Van der Veken, N.J., Van Remoortel, B., Strelkov, S.V., De Maeyer, M., Chaltin, P., and Debyser, Z. (2010) Rational design of small-molecule inhibitors of the LEDGF/ p75-integrase interaction and HIV replication. Nature Chemical Biology, 6, 442-448.
66. Geppert, T., Bauer, S., Hiss, J.A., Conrad, E., Reutlinger, M., Schneider, P., Weisel, M., Pfeiffer, B., Altmann, K.H.,Waibler, Z., and Schneider, G. (2012) Immunosuppressive small molecule discovered by structure-based virtual screening for inhibitors of protein-protein interactions. Angewandte Chemie International Edition, 51, 258-261.
67. Czarna, A., Beck, B., Srivastava, S., Popowicz, G.M.,Wolf, S., Huang, Y., Bista, M., Holak, T.A., and Domling, A. (2010) Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/ Hdm2 antagonists. Angewandte Chemie International Edition, 49, 5352-5356.
68. Thorsen, T.S., Madsen, K.L., Rebola, N., Rathje, M., Anggono, V., Bach, A., Moreira, I.S., Stuhr-Hansen, N., Dyhring, T., Peters, D., Beuming, T., Huganir, R., Weinstein, H., Mulle, C., Strømgaard, K., Rønn, L.C., and Gether, U. (2010) Identification of a small-molecule inhibitor of the PICK1 PDZ domain that inhibits hippocampal LTP and LTD. Proceedings of the National Academy of Sciences of the United States of America, 107, 413-418.
69. Moerke, N.J., Aktas, H., Chen, H., Cantel, S., Reibarkh, M.Y., Fahmy, A., Gross, J.D., Degterev, A., Yuan, J., Chorev, M., Halperin, J.A., and Wagner, G. (2007) Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell, 128, 257-267.
70. von Kleist, L., Stahlschmidt, W., Bulut, H., Gromova, K., Puchkov, D., Robertson, M. J., MacGregor, K.A., Tomilin, N., Pechstein, A., Chau, N., Chircop, M., Sakoff, J., von Kries, J.P., Saenger, W., Krausslich, H.G., Shupliakov, O., Robinson, P.J., McCluskey, A., and Haucke, V. (2011) Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition. Cell, 146, 471-484.
71. Corradi, V., Mancini, M., Manetti, F., Petta, S., Santucci, M.A., and Botta, M. (2010) Identification of the first non-peptidic small molecule inhibitor of the c-Abl/ 14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis. Bioorganic and Medicinal Chemistry Letters, 20, 6133-6137.
72. Betzi, S., Restouin, A., Opi, S., Arold, S.T., Parrot, I., Guerlesquin, F., Morelli, X., and Collette, Y. (2007) Protein-protein interaction inhibition (2P2I) combining high throughput and virtual screening: application to the HIV-1 Nef protein. Proceedings of the National Academy of Sciences of the United States of America, 104, 19256-19261.